2-(10H-苯并噻嗪-10-基)乙酰肼 | 125096-15-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻嗪类
• 中文名称: 2-(10H-苯并噻嗪-10-基)乙酰肼
• 英文名称: acetohydrazido phenothiazine
• 英文别名: 2-(10H-phenothiazin-10-yl)acetohydrazide；2-(10H-phenothiazin-10-yl)acetic acid hydrazide；2-phenothiazin-10-ylacetohydrazide
• CAS: 125096-15-3
• 化学式: C₁₄H₁₃N₃OS
• 分子量: 271.343
• InChiKey: DGGWSYPHEPMOBE-UHFFFAOYSA-N

物化性质

• 熔点：
  216 °C

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  83.7
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  2-(10H-苯并噻嗪-10-基)乙酰肼 在 溶剂黄146 、 zinc(II) chloride 作用下， 以 1,4-二氧六环 、 乙醇 为溶剂， 反应 17.0h， 生成 N-[4-Oxo-2-((E)-styryl)-thiazolidin-3-yl]-2-phenothiazin-10-yl-acetamide
  参考文献：
  名称：

  Mishra, Seema; Srivastava, S. K.; Srivastava, S. D., Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1997, vol. 36, # 9, p. 826 - 830

  摘要：

  DOI：
• 作为产物：
  描述：

  ethyl 2-(10H-phenothiazin-10-yl)acetate 在 一水合肼 作用下， 以 乙醇 为溶剂， 反应 18.0h， 以90%的产率得到2-(10H-苯并噻嗪-10-基)乙酰肼
  参考文献：
  名称：

  [EN] INHIBITORS OF MALT1 PROTEASE
  [FR] INHIBITEURS DE LA PROTÉASE MALT1

  摘要：

  本发明涉及作为粘膜相关淋巴组织淋巴瘤易位蛋白1（MALT1）抑制剂的化合物及其在治疗中的应用，尤其是在治疗或预防可通过抑制paracaspase治疗的疾病或失调中的应用。本发明还涉及含有该化合物的药物组合物。

  公开号：

  WO2014086478A1

文献信息

• [EN] INHIBITORS OF MALT1 PROTEASE<br/>[FR] INHIBITEURS DE LA PROTÉASE MALT1
  申请人：HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT GMBH

  公开号：WO2014086478A1

  公开（公告）日：2014-06-12

  The present invention relates to compounds which are inhibitors of mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALTl) and to their use in therapy, in particular in the treatment or prevention of a disease or disorder which is treatable by an inhibitor of a paracaspase. The present invention also relates to pharmaceutical compositions containing such compounds.

  本发明涉及作为粘膜相关淋巴组织淋巴瘤易位蛋白1（MALT1）抑制剂的化合物及其在治疗中的应用，尤其是在治疗或预防可通过抑制paracaspase治疗的疾病或失调中的应用。本发明还涉及含有该化合物的药物组合物。
• Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives
  申请人：Doyle Kevin James

  公开号：US20090318429A1

  公开（公告）日：2009-12-24

  The present invention relates to compositions and methods for treating a disease in an animal, which disease is responsive to inhibiting of functional cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide by administering to a mammal in need thereof an effective amount of a compound defined herein (including those compounds set forth in Tables 1-14 or encompassed by formulas I-XII) or compositions thereof, thereby treating the disease. The present invention particularly, relates to a method of treating diarrhea and polycystic kidney disease.

  本发明涉及用于治疗动物患病的组合物和方法，该疾病对通过向需要的哺乳动物投予本文所定义的化合物的有效量（包括表1-14中列出的那些化合物或被I-XII公式所包含的化合物）或其组合物来抑制功能性囊性纤维化跨膜传导调节蛋白（CFTR）多肽作出反应，从而治疗该疾病。本发明特别涉及一种治疗腹泻和多囊性肾病的方法。
• Compounds, compositions and methods comprising heteroaromatic derivatives
  申请人：Doyle Kevin James

  公开号：US20100144733A1

  公开（公告）日：2010-06-10

  The present invention relates to compositions and methods for treating a disease in an animal, which disease is responsive to inhibiting of functional cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide by administering to a mammal in need thereof an effective amount of a compound defined herein (including those compounds set forth in Tables 1-14 or encompassed by formulas I-XII) or compositions thereof, thereby treating the disease. The present invention particularly, relates to a method of treating diarrhea and polycystic kidney disease.

  本发明涉及用于治疗动物体内对抑制功能性囊性纤维化跨膜传导调节因子（CFTR）多肽敏感的疾病的组合物和方法，通过向需要治疗该疾病的哺乳动物中投与本文所定义的化合物的有效量（包括表1-14中列出的化合物或公式I-XII所包含的化合物）或其组合物，从而治疗该疾病。本发明特别涉及治疗腹泻和多囊肾病的方法。
• Hogale; Deshmukh, Journal of the Indian Chemical Society, 1989, vol. 66, # 3, p. 212 - 213
  作者：Hogale、Deshmukh

  DOI：——

  日期：——
• Synthesis and biological evaluation of new phenothiazine derivatives bearing a pyrazole unit as protein farnesyltransferase inhibitors
  作者：Lavinia Baciu-Atudosie、Alina Ghinet、Amaury Farce、Joëlle Dubois、Dalila Belei、Elena Bîcu

  DOI：10.1016/j.bmcl.2012.09.030

  日期：2012.11

  A new family of protein farnesyltransferase inhibitors, based on a phenothiazine scaffold, was designed and synthesized. The biological evaluation of these products showed that compounds 28 and 30 were the most active, with protein farnesyltransferase inhibition potencies in the low micromolar range. Compounds were also evaluated for their antiproliferative activity on a NCI-60 cancer cell line panel. Indenopyrazole 30 exhibited the most potent in vitro cytostatic activity inhibiting the growth of HCT-116, LOX IMVI and SK-MEL-5 cell lines. (C) 2012 Elsevier Ltd. All rights reserved.